Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced that Dr. Jay R. Luly, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. ET. The presentation will highlight updates on Enanta's research and development programs for 2021, followed by a Q&A session. A live audio webcast will be available on Enanta's website, with a replay archived for 30 days. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with current research targeting RSV, HBV, NASH, and COVID-19.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 8:20 a.m. Eastern Time. The presentation will include an update on Enanta’s research and development programs and plans for 2021. A separate question and answer session will follow the presentation and will be webcast.

A live audio webcast will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005271/en/

FAQ

When will Enanta Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Enanta Pharmaceuticals will present on January 12, 2021, at 8:20 a.m. Eastern Time.

Who is presenting for Enanta Pharmaceuticals at the conference?

Dr. Jay R. Luly, President and CEO, will be the presenter.

How can I watch the Enanta Pharmaceuticals presentation?

The presentation can be accessed through the 'Events and Presentations' section of Enanta's website.

What topics will be covered in the Enanta Pharmaceuticals presentation?

The presentation will cover updates on Enanta's research and development programs and plans for 2021.

What is the focus of Enanta Pharmaceuticals' research?

Enanta focuses on developing small molecule drugs for viral infections and liver diseases.

Which diseases are included in Enanta Pharmaceuticals' research?

Enanta's research includes targets such as RSV, HBV, NASH, and COVID-19.